Terms: = Lymphoma AND HSP90AB1, HSPCB, 3326, ENSG00000096384, HSP90B, HSP90-BETA, P08238, D6S182, HSPC2, FLJ26984 AND Treatment
4 results:
1. Analysis of signaling cascades from myeloma cells treated with pristimerin.
Almaghrbi H; Elkardawy R; Udhaya Kumar S; Kuttikrishnan S; Abunada T; Kashyap MK; Ahmad A; Uddin S; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2023; 134():147-174. PubMed ID: 36858733
[TBL] [Abstract] [Full Text] [Related]
2. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
[TBL] [Abstract] [Full Text] [Related]
3. Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma.
Allchin RL; Kelly ME; Mamand S; Doran AG; Keane T; Ahearne MJ; Wagner SD
PLoS One; 2019; 14(4):e0215765. PubMed ID: 31013298
[TBL] [Abstract] [Full Text] [Related]
4. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
[TBL] [Abstract] [Full Text] [Related]
